This Week Undercard $3 Stocks: $SNYR, $SONN, $LGPS
Post# of 9
(Total Views: 40)
Posted On: 07/07/2025 2:52:52 PM
This Week Undercard $3 Stocks: $SNYR, $SONN, $LGPS, $SVRE Making Strategic Moves
https://thestreetreports.com/this-week-underc...gic-moves/
In today’s volatile small-cap landscape, several companies trading under $3 are making bold strategic moves across the consumer health, biotech, industrial, and mobility tech sectors—each positioning for significant growth.
Synergy CHC Corp. (NASDAQ: SNYR) has emerged as a disruptive force in the $100B+ global functional beverage market with its flagship FOCUSfactor Energy Drink. Recently, the company appointed former Coca-Cola VP Scott Woodburn as President of Beverage to lead global scale-up efforts. With distribution through major retailers including Costco (NASDAQ: COST), Walmart (NYSE: WMT), and Amazon (NASDAQ: AMZN), Synergy is gaining national attention—set to appear on Bloomberg TV and FOX Business. Roth Capital reiterated a Buy rating and a $10 price target, (read more) reflecting confidence in Synergy’s high-growth trajectory. Other consumer brands under its umbrella include Flat Tummy®, Sneaky Vaunt®, and Hand MD®.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) continues advancing its FHAB (Fully Human Albumin-Binding) platform for precision oncology therapies. Its lead asset, SON-1010 (IL-12-FHAB), is in an ongoing Phase 1/2a trial in combination with Roche’s Tecentriq® for platinum-resistant ovarian cancer. Meanwhile, SON-1210, a next-gen IL12-FHAB-IL15 candidate, is advancing toward a Phase 1/2a study for pancreatic cancer in collaboration with the Sarcoma Oncology Center. The company’s platform supports scalable development of biologic therapies including cytokines, peptides, antibodies, and vaccines.
LogProstyle Inc. (NYSE American: LGPS), headquartered in Tokyo, announced Board approval for a $543,455 share repurchase program, authorizing the buyback of up to 1,086,910 common shares on the NYSE American through June 2026. This capital allocation initiative reflects the company’s ongoing efforts to enhance shareholder value and financial discipline.
Saverone 2014 Ltd (NASDAQ: SVRE) is tackling one of the most critical public safety issues—distracted driving—with its advanced driver protection and ADAS (Advanced Driver-Assistance Systems) technologies. Its patented system blocks drivers from using cell phones while driving, aiming to reduce accidents caused by mobile device distractions. As global demand rises for AI-driven mobility safety solutions, Saverone’s technologies position it as a player in the next evolution of vehicle safety innovation.
With strategic hires, clinical trials, buyback authorizations, and tech deployment underway, Synergy CHC Corp. (NASDAQ: SNYR), Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), LogProstyle Inc. (NYSE American: LGPS), and Saverone 2014 Ltd (NASDAQ: SVRE) stand out as under-$3 stocks with disruptive potential across multiple sectors.
https://thestreetreports.com/this-week-underc...gic-moves/
In today’s volatile small-cap landscape, several companies trading under $3 are making bold strategic moves across the consumer health, biotech, industrial, and mobility tech sectors—each positioning for significant growth.
Synergy CHC Corp. (NASDAQ: SNYR) has emerged as a disruptive force in the $100B+ global functional beverage market with its flagship FOCUSfactor Energy Drink. Recently, the company appointed former Coca-Cola VP Scott Woodburn as President of Beverage to lead global scale-up efforts. With distribution through major retailers including Costco (NASDAQ: COST), Walmart (NYSE: WMT), and Amazon (NASDAQ: AMZN), Synergy is gaining national attention—set to appear on Bloomberg TV and FOX Business. Roth Capital reiterated a Buy rating and a $10 price target, (read more) reflecting confidence in Synergy’s high-growth trajectory. Other consumer brands under its umbrella include Flat Tummy®, Sneaky Vaunt®, and Hand MD®.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) continues advancing its FHAB (Fully Human Albumin-Binding) platform for precision oncology therapies. Its lead asset, SON-1010 (IL-12-FHAB), is in an ongoing Phase 1/2a trial in combination with Roche’s Tecentriq® for platinum-resistant ovarian cancer. Meanwhile, SON-1210, a next-gen IL12-FHAB-IL15 candidate, is advancing toward a Phase 1/2a study for pancreatic cancer in collaboration with the Sarcoma Oncology Center. The company’s platform supports scalable development of biologic therapies including cytokines, peptides, antibodies, and vaccines.
LogProstyle Inc. (NYSE American: LGPS), headquartered in Tokyo, announced Board approval for a $543,455 share repurchase program, authorizing the buyback of up to 1,086,910 common shares on the NYSE American through June 2026. This capital allocation initiative reflects the company’s ongoing efforts to enhance shareholder value and financial discipline.
Saverone 2014 Ltd (NASDAQ: SVRE) is tackling one of the most critical public safety issues—distracted driving—with its advanced driver protection and ADAS (Advanced Driver-Assistance Systems) technologies. Its patented system blocks drivers from using cell phones while driving, aiming to reduce accidents caused by mobile device distractions. As global demand rises for AI-driven mobility safety solutions, Saverone’s technologies position it as a player in the next evolution of vehicle safety innovation.
With strategic hires, clinical trials, buyback authorizations, and tech deployment underway, Synergy CHC Corp. (NASDAQ: SNYR), Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), LogProstyle Inc. (NYSE American: LGPS), and Saverone 2014 Ltd (NASDAQ: SVRE) stand out as under-$3 stocks with disruptive potential across multiple sectors.
(0)
(0)